Orgenesis announces JV partnership with Harley Street Healthcare Group

Orgenesis announced a strategic partnership agreement with Harley Street Healthcare Group. This partnership aims to accelerate the clinical development and commercialization of advanced wellness and longevity therapies and products to a global customer base, aimed at significantly reducing the impact of lifestyle-related illnesses on people’s health. Under the terms of the agreement, Orgenesis and HSHG will establish a joint venture, with Orgenesis owning 49% and HSHG owning 51% of the entity. The JV will focus on launching innovative health and wellness services, including personalized preventative care and regenerative therapies. The goal is to establish a comprehensive “Health-Wellness-as-a-Service” model, leveraging HSHG’s established healthcare network and Orgenesis’ cutting-edge biotech innovations. The JV intends to introduce a suite of wellness and longevity products by the end of 2024 that will include immune cell banking, aging and longevity therapies, preventative illness screening, and regenerative therapies using stem cells. The initial rollout will target key global regions, including the United Kingdom, UAE, MENA, Canada, ASEAN, the Balkans, Africa, Latam, and the Indian subcontinent. In connection with the agreement, HSHG has agreed to invest up to $10 million over three years into Orgenesis and the joint venture.